Financials data is unavailable for this security.
View more
Year on year Guizhou Yibai Pharmaceutical Co Ltd grew revenues 3.12% from 2.74bn to 2.82bn while net income improved from a loss of 426.47m to a gain of 103.40m.
| Gross margin | 63.72% |
|---|---|
| Net profit margin | -5.63% |
| Operating margin | -4.97% |
| Return on assets | -3.01% |
|---|---|
| Return on equity | -4.44% |
| Return on investment | -4.09% |
More ▼
Cash flow in CNYView more
In 2023, Guizhou Yibai Pharmaceutical Co Ltd increased its cash reserves by 18.85%, or 110.33m. The company earned 377.61m from its operations for a Cash Flow Margin of 13.39%. In addition the company used 115.59m on investing activities and also paid 151.69m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.44 |
|---|---|
| Tangible book value per share | 2.83 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.82 |
|---|---|
| Quick ratio | 1.26 |
| Total debt/total equity | 0.352 |
|---|---|
| Total debt/total capital | 0.2515 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 124.25%.
| Div yield(5 year avg) | 3.08% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 69.21 |
More ▼
